Targeting NAD+ Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma

Barry E. Kennedy, Maryanne Sadek, Manal O. Elnenaei, Anthony Reiman, Shashi A. Gujar

Producción científica: Contribución a una revistaEncuesta cortarevisión exhaustiva

16 Citas (Scopus)

Resumen

Antibodies targeting CD38, a NAD+-degrading enzyme, have emerged as a promising immunotherapy against multiple myeloma (MM). Currently, the mechanisms by which anti-CD38 antibodies establish their therapeutic effects are poorly understood. Here, we advocate for the depletion of NAD+ to enhance the efficacy of anti-CD38-based immunotherapies in MM.

Idioma originalEnglish
Páginas (desde-hasta)9-12
Número de páginas4
PublicaciónTrends in Cancer
Volumen6
N.º1
DOI
EstadoPublished - ene. 2020

Nota bibliográfica

Funding Information:
This work was supported by grants from the Canadian Cancer Society (CRS), the Canadian Cancer Society Research Institute (CCSRI), the Canadian Institutes of Health Research (CIHR), and the Beatrice Hunter Cancer Research Institute (BHCRI) to S.A.G. B.E.K. is a trainee in the Cancer Research Training Program (CRTP) of the BHCRI with funding from the Terry Fox Research Institute (TFRI). S.A.G. is supported by Dalhousie Medical Research Foundation (DMRF).

Publisher Copyright:
© 2019

ASJC Scopus Subject Areas

  • Oncology
  • Cancer Research

Huella

Profundice en los temas de investigación de 'Targeting NAD+ Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma'. En conjunto forman una huella única.

Citar esto